ALEMBIC | TTK HEALTHCARE | ALEMBIC/ TTK HEALTHCARE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 57.8 | 69.9 | 82.7% | View Chart |
P/BV | x | 5.0 | 1.7 | 285.5% | View Chart |
Dividend Yield | % | 0.2 | 0.9 | 23.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-18 |
TTK HEALTHCARE Mar-19 |
ALEMBIC/ TTK HEALTHCARE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 72 | 1,215 | 5.9% | |
Low | Rs | 34 | 610 | 5.6% | |
Sales per share (Unadj.) | Rs | 4.7 | 444.4 | 1.1% | |
Earnings per share (Unadj.) | Rs | 6.1 | 17.2 | 35.4% | |
Cash flow per share (Unadj.) | Rs | 6.2 | 27.6 | 22.6% | |
Dividends per share (Unadj.) | Rs | 0.20 | 5.00 | 4.0% | |
Dividend yield (eoy) | % | 0.4 | 0.5 | 68.9% | |
Book value per share (Unadj.) | Rs | 40.7 | 177.9 | 22.9% | |
Shares outstanding (eoy) | m | 267.03 | 14.13 | 1,889.8% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 11.3 | 2.1 | 548.5% | |
Avg P/E ratio | x | 8.7 | 52.9 | 16.4% | |
P/CF ratio (eoy) | x | 8.5 | 33.0 | 25.7% | |
Price / Book Value ratio | x | 1.3 | 5.1 | 25.4% | |
Dividend payout | % | 3.3 | 29.0 | 11.3% | |
Avg Mkt Cap | Rs m | 14,139 | 12,894 | 109.7% | |
No. of employees | `000 | NA | 2.3 | 0.0% | |
Total wages/salary | Rs m | 207 | 1,307 | 15.9% | |
Avg. sales/employee | Rs Th | NM | 2,715.7 | - | |
Avg. wages/employee | Rs Th | NM | 565.3 | - | |
Avg. net profit/employee | Rs Th | NM | 105.4 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,255 | 6,279 | 20.0% | |
Other income | Rs m | 370 | 78 | 477.7% | |
Total revenues | Rs m | 1,625 | 6,356 | 25.6% | |
Gross profit | Rs m | 111 | 496 | 22.4% | |
Depreciation | Rs m | 38 | 147 | 25.8% | |
Interest | Rs m | 2 | 34 | 5.0% | |
Profit before tax | Rs m | 442 | 393 | 112.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1,212 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 24 | 149 | 16.1% | |
Profit after tax | Rs m | 1,630 | 244 | 668.8% | |
Gross profit margin | % | 8.9 | 7.9 | 112.1% | |
Effective tax rate | % | 5.4 | 37.9 | 14.3% | |
Net profit margin | % | 129.8 | 3.9 | 3,345.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,867 | 2,717 | 68.7% | |
Current liabilities | Rs m | 591 | 1,571 | 37.6% | |
Net working cap to sales | % | 101.6 | 18.3 | 556.7% | |
Current ratio | x | 3.2 | 1.7 | 182.6% | |
Inventory Days | Days | 94 | 32 | 293.1% | |
Debtors Days | Days | 74 | 47 | 157.6% | |
Net fixed assets | Rs m | 1,791 | 991 | 180.7% | |
Share capital | Rs m | 534 | 141 | 378.0% | |
"Free" reserves | Rs m | 10,324 | 2,373 | 435.0% | |
Net worth | Rs m | 10,858 | 2,514 | 431.8% | |
Long term debt | Rs m | 41 | 3 | 1,211.8% | |
Total assets | Rs m | 11,591 | 4,158 | 278.7% | |
Interest coverage | x | 260.9 | 12.6 | 2,068.0% | |
Debt to equity ratio | x | 0 | 0 | 280.6% | |
Sales to assets ratio | x | 0.1 | 1.5 | 7.2% | |
Return on assets | % | 14.1 | 6.7 | 210.9% | |
Return on equity | % | 15.0 | 9.7 | 154.9% | |
Return on capital | % | 15.2 | 16.9 | 89.7% | |
Exports to sales | % | 1.5 | 3.6 | 43.1% | |
Imports to sales | % | 21.0 | 0.5 | 4,256.2% | |
Exports (fob) | Rs m | 19 | 225 | 8.6% | |
Imports (cif) | Rs m | 263 | 31 | 850.9% | |
Fx inflow | Rs m | 19 | 225 | 8.6% | |
Fx outflow | Rs m | 264 | 71 | 371.0% | |
Net fx | Rs m | -244 | 154 | -158.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 236 | 173 | 136.2% | |
From Investments | Rs m | -224 | 97 | -232.1% | |
From Financial Activity | Rs m | -27 | -307 | 8.7% | |
Net Cashflow | Rs m | -15 | -38 | 39.3% |
Indian Promoters | % | 64.0 | 65.4 | 97.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.2 | 3.7 | 5.4% | |
FIIs | % | 9.7 | 5.2 | 186.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 26.1 | 25.8 | 101.2% | |
Shareholders | 54,701 | 12,723 | 429.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC With: JUBILANT LIFE SCIENCES PANACEA BIOTECH WOCKHARDT ABBOTT INDIA FRESENIUS KABI ONCO.
Compare ALEMBIC With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
On Friday, Indian share markets witnessed huge selling pressure and ended deep in the red, amid a global selloff.
For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended December 2019, TTK HEALTHCARE has posted a net profit of Rs 45 m (down 8.3% YoY). Sales on the other hand came in at Rs 2 bn (up 11.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More